This study explores the contribution of a single determination of plasma levels for measuring adherence by means of forecasting virologic failure. Adherence was measured by questionnaires, punctuality at appointments to withdraw drugs, and plasma levels. Virologic failure was considered when 2 detectable consecutive viral loads were observed in 2 consecutive determinations with at least 1 month between them. Univariant analysis, logistic regression, and receiver operating characteristic curves were carried out. In 29 cases, virologic failure was observed. The lowest incidence was found in patients considered adherent by plasma levels and highest in those who declared nonfulfillment. The combination of methods increased the association of the incidence of virologic failure with nonadherence. The use of questionnaires plus pharmacy information implies a gain in sensitivity and a slight loss of specificity. There is a high incidence of virologic failure in these patients and a strong link with their classification as nonadherent with methods such as questionnaires and pharmacy collection information. Plasma levels do not contribute much to the prediction of virologic failure.
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Knowledge of the degree of patients' adherence to antiretroviral therapy (ART) is an important tool for making clinical decisions. 1 Nevertheless, there is no single, inexpensive, and easily applicable criterion with validity for establishing adherence, so the joint use of several methods is recommended.
2,3 Among the methods used are self-filled questionnaires concerning the days before the interview and punctuality of collecting medicines from the pharmacy. 3 Another, rather controversial method is the determination of plasma concentrations of antiretroviral medications. 2 In an attempt to answer questions arising from previous research, 4 this study explores the contribution of a single determination of plasma levels for measuring adherence by means of forecasting virologic failure.
Patients and Methods
A prospective study of cohorts was designed to include all outpatients at 2 general hospitals, those of León and El Bierzo, in Spain, who had been under triple treatment with indinavir and 2 nucleoside analogs for at least 6 months. The recruitment phase lasted from January to June 2000, and monitoring was conducted until May 2002. The study was approved by the Ethics Committee, and the informed consent of the patients was requested in all cases.
Adherence to ART was measured in 3 ways:
1. Doses missed during the 4 days immediately preceding the visit were recorded by a nurse in a face-to-face interview. Patients were considered nonadherent if they had taken less than 90% of their prescribed doses of at least 1 drug. 5 2. Adherence to therapy was also assessed from information on the hospital pharmacy dispensation office database. Patients were identified as nonadherent if they had accumulated a delay of more than 9 days in collecting their treatment at the pharmacy over the previous 3 months (>10%). 3. At each visit, 5-mL blood samples were taken from each patient between 8 and 10 AM and collected in lithium heparin Monovettes (Sarstedt, Nümbreht, Germany). Plasma was isolated by centrifugation, viro-inactivated in a water bath at 60°C for 60 minutes, and stored at -20°C until analysis. Plasma indinavir levels were determined by reversephase high-performance liquid chromatography according to a validated method, 6 enabling the simultaneous quantification in plasma of HIV protease inhibitors (PI) and efavirenz. Because the exact schedule of the last dose taken by the patient was not available, and the range of residual concentrations of indinavir (8 hours after the last dose) was estimated between 50 and 300 ng/mL, we used a 250 ng/mL threshold to determine suboptimal indinavir serum concentration. 7 Such a low threshold allowed us to take into account interindividual variability in PI concentrations as a result of patient differences in drug absorption and clearance.
Concomitant medications at the time of sample collection were recorded. Finally, viral load, CD4 count, and other clinical and laboratory variables were determined by standard means.
Virologic failure was considered to have occurred when 2 detectable (>400 copies/mL) consecutive viral loads were observed in 2 consecutive determinations with at least 1 month between them. The monitoring time for the patients with virologic failure ran from their inclusion and the average time between the last undetectable viral load and the first detectable one.
Patients for whom it was not possible to obtain 2 determinations of viral load with an interval of at least 1 month were considered missing, as were those where virologic failure could not be confirmed by a second determination.
Programs used were Epi Info version 6.02 8 (Centers for Disease Control and Prevention, Atlanta, Ga) for the univariant analysis and the calculation of incidences and risk ratio, Epi Info 2000 9 for the logistic regression analysis, and Epidat (Xunta de Galicia y Organización Panamericana de Salud, Santiago de Compostela, Spain) for calculating the receiver operating characteristic curves and the area under the curve.
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Results
At the beginning of the study, 305 patients were undergoing ART, 280 of whom had been receiving it for at least 6 months. Two hundred sixty-seven (95.4%) agreed to take part in the study, of which 160 were under treatment with PIs and 2 with nucleoside reverse transcriptase inhibitors (NRTIs). Serum for the analysis of plasma levels was available from 153 patients, and 140 fulfilled monitoring criteria, of which 112 were taking indinavir as an IP. Men comprised 70.5% of the patients, with an age range between 17 and 72, a mean age of 38 (SD = 8 years), and a median age of 37; 43.8% were intravenous drug users and 35.7% were heterosexual.
Total monitoring time was 1832 months (mean 16 months, SD 8.8, median 21 months, and range 1-27 months). In 29 cases, virologic failure was observed, which meant an accumulated incidence of 25.9% and a density of incidence of 1.58 cases per 100 patients per month of follow-up. Table 1 shows the distribution of the incidence of virologic failure according to the 3 criteria used individually to assess adherence. The lowest incidence was found in patients considered adherent by the criteria of detectable plasma levels and the highest in those who declared nonfulfillment in the past 4 days of more than 10%. In all cases, there were obvious epidemiological and statistical differences, which were maintained after the logistic regression analysis, between the virologic failure and adherence measured by any criteria.
The combination of the different methods used increased the association of the incidence of virologic failure with nonadherence, attributable fundamentally to a lower incidence of failure among adherents (Table 2) . Table 3 shows the validity of the methods of measuring adherence to predict virologic failure and the area under the resulting curve (AUC). The only criteria with acceptable sensitivity entail a low specificity, and vice versa, with resultant AUCs of less than 0.7. The joint use of the questionnaire and pharmacy collection information implies a notable gain in sensitivity and a slight loss of specificity, whereby the area AUC is higher than for the 2 markers used individually. Adding plasma level detection improves sensitivity to the detriment of specificity, so the AUC is less than 0.7 ( Figure 1 ). Figure 2 shows the algorithm including the determination of adherence by punctuality at the pharmacy, the questionnaire, and the sequenced determination of plasma levels.
González et al
Discussion
The use of viral rebound as a gold standard for estimating adherence to highly active ART (HAART) is limited because some nonadherent subjects maintain viral suppression 11 and because virologic failure may have other causes. However, because there is no universally accepted standard method for assessing adherence and it has obviously become the most important factor for predicting virologic failure, 12, 13 its use as a standard may be advised. On the other hand, poor adherence favors the development of resistance, especially with indinavir, 14 another cause of virologic failure. Furthermore, this possible limitation is attenuated by the prospective design of the study, so obtaining data follows the time-scale of events, from adherence as a cause to virologic failure as an effect.
The virologic failure observed in our study reached levels near 26%, figures very similar to those obtained in studies considering a single determination as a virologic failure. 15 Our criterion of 2 consecutive positive determinations, although more restrictive, lowers the possibility of false positives. In any event, the incidence of virologic failure observed, 1.58 cases per 100 patients per month of monitoring, is high enough, because of its clinical and social consequences, to focus the necessary attention on the circumstances that may be causing it.
The highest incidence of virologic failure was observed in those patients who declared that they were nonadherent in the questionnaire, which confirmed J INT ASSOC PHYSICIANS AIDS CARE 6(4); 2007
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Adherence and Virologic Failure the good specificity of the method 2 while contrasting with its low sensitivity, pointed out elsewhere. 16 The questionnaire, based on the one proposed by the AIDS Clinical Trials Group, is simple and inexpensive to administer but is not effective at correctly identifying those patients who overestimate their adherence or simply falsify their answers.
The results obtained with the other methods used, the pharmacy register and the concentration of plasma levels, show increases in sensitivity and losses of specificity. They are therefore useful for identifying nonadherent patients who do not identify themselves.
The pharmacy register method gives the greatest AUC; is a simple tool, habitually applied; and does not require the participation of the patients. 17 It is based on the assumption that patients cannot take any medicine that they do not collect and that they take that which they do collect, although there is a tendency to overestimate because patients tend to accumulate medicines that they do not need. 18 Despite the limitation of plasma level measures to confirm adherence days or weeks before the collection of blood samples, the determination of plasma levels of indinavir meant a greater gain in sensitivity for detecting nonadherent subjects. In other studies, the relationship between adherence and plasma levels was found by adjusting the levels found 19 or by considering the trough concentration 20, 21 . Nevertheless, the results do not point to this, and this criterion, which is time independent, facilitates the application of the method. The results obtained for sensitivity (76%) and specificity (45%) are similar to those obtained by Duong et al 22 of 90% and 43%, respectively. The lower sensitivity observed in our study is probably attributable to the use of viral loads obtained after the passing of time and to the fact that in the study by Duong et al, all the PIs were analyzed. The use of indinavir levels obtained at random as predictors of adherence was investigated by Liechty et al, 21 who found a lower sensitivity (56%) and better specificity (71%).
As has already been pointed out, in this study and in many others, the use of a single tool to assess adherence to HAART does not afford an acceptable internal validity, which is why the joint use of several methods is recommended. [23] [24] [25] In our case, from the combination of methods, the best overall results were obtained with the combined application of the questionnaire and the pharmacy register (AUC = 0.715). The addition of plasma levels to this combination meant a gain in sensitivity and a loss of specificity, which resulted in a decrease in the AUC (0.658). Similar results have been obtained in other situations, with the determination of plasma concentrations in the assessment of adherence in the case of the NRTIs 26 and even indinavir, 4 so, as opposed to the assessment made by the questionnaire together with pharmacy registers, the determination of levels will not mean a gain in internal validity of the measure of adherence. The pharmacokinetic characteristics of the drug probably have a lot to do with the results obtained. Among other factors, dietary requirements, interactions, interindividual and intraindividual variation, the short half-life of the drug, and the variable sampling times may have brought on undetectable levels of indinavir that would somehow hide a patient's adherence behavior. A better knowledge of the pharmacokinetics of indinavir could favor the future use of monitoring in the assessment of adherence, as is borne out by the fact that 19 of the 112 patients in the study were classified as nonadherent based on plasma levels but not the other methods, and because the incidence observed of virologic failure is not very high (0.83 per 100 patients per month), we do not believe there is any justification in using complex and expensive methods to identify adherence to treatment.
As a corollary, we point to the high incidence of virologic failure in this group of patients and its strong link with their classification as nonadherent with simple and acceptable methods such as questionnaires and punctuality in collecting medicine at the pharmacy. Figure 2 Algorithm for assessing adhesion to antiretroviral treatment. N, number; VF, virologic failure; F-up, months of follow-up; I, incidence per 100 patients/mo.
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